Gene Therapy

Learnings from the COVID-19 pandemic for the advanced therapies sector 2:04
Learnings from the COVID-19 pandemic for the advanced therapies sector
Miguel Forte • 5 Oct 2021
Driving the development of gene therapies for more common conditions 3:00
Driving the development of gene therapies for more common conditions
Paul Gissen • 6 Oct 2021
LUMEVOQ gene therapy for LHON 2:40
LUMEVOQ gene therapy for LHON
Magali Taiel • 6 Oct 2021
The current landscape of advanced therapies in the UK 1:34
The current landscape of advanced therapies in the UK
Matthew Durdy • 6 Oct 2021
The importance of analytical tools in cell and gene therapy manufacturing 1:17
The importance of analytical tools in cell and gene therapy manufacturing
Manuel Carrondo • 6 Oct 2021
HSC gene editing: current approaches and remaining challenges 4:08
HSC gene editing: current approaches and remaining challenges
Valentina Vavassori • 27 May 2021
Enhancing AAV gene therapy in children with inborn errors of metabolism 2:25
Enhancing AAV gene therapy in children with inborn errors of metabolism
Gloria Gonzalez-Aseguinolaza • 18 May 2021
Combining rAAV gene therapy with standard-of-care for the treatment of citrullinemia 1:35
Combining rAAV gene therapy with standard-of-care for the treatment of citrullinemia
Gloria Gonzalez-Aseguinolaza • 18 May 2021
T cell and HSC gene editing for the treatment of Hyper-IgM Type 1 5:28
T cell and HSC gene editing for the treatment of Hyper-IgM Type 1
Valentina Vavassori • 27 May 2021
HSC gene editing highlights from ASGCT 2021 2:16
HSC gene editing highlights from ASGCT 2021
Valentina Vavassori • 27 May 2021
The potential of oncolytic adenoviral vectors 1:32
The potential of oncolytic adenoviral vectors
Margarita Romanenko • 13 May 2021
Vector-based therapies for metabolic disorders 3:09
Vector-based therapies for metabolic disorders
Gloria Gonzalez-Aseguinolaza • 18 May 2021
CRISPR-Cas9 gene-edited HSPCs for Friedreich’s ataxia 5:31
CRISPR-Cas9 gene-edited HSPCs for Friedreich’s ataxia
Stephanie Cherqui • 17 May 2021
Chemically modified mRNA encoding BMP-2 for bone healing 4:10
Chemically modified mRNA encoding BMP-2 for bone healing
Christopher Evans • 19 May 2021
Neuraminidase could improve AAV9 gene therapy for Batten disease 1:45
Neuraminidase could improve AAV9 gene therapy for Batten disease
Kathrin Meyer • 18 May 2021
The gene therapy landscape for osteoarthritis 3:36
The gene therapy landscape for osteoarthritis
Christopher Evans • 19 May 2021
The content of VJRegenMed is intended for healthcare professionals